OQROGet OQRO Pro
Insider trade

Jazz Pharmaceuticals (JAZZ)Officer sold ~$13K

Patricia Carr, Officer at Jazz Pharmaceuticals, sold ~$13K of Jazz Pharmaceuticals shares.

~$13K
Approx. value · 69 sh @ $181.66
7,012
Holds after · shares reported
Traded
Nov 18, 2025
Filed
Nov 21, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 23, 2025, the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Ted Love to the Board, effective as of December 1, 2025, as a Class I director for a term expiring at the annual general meeting of shareholders to be held in 2027.”
  2. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
  3. Nov 17, 2025Insider · Their largest sale since 2022Officer sold ~$1.2M of JAZZ shares in the open market
  4. Nov 18, 2025 · this disclosureInsiderOfficer sold ~$13K of JAZZ shares in the open market

What came next

  1. Nov 18, 2025Insider · 3 peopleInsiders: 6 sales (~$5.2M)
  2. Nov 20, 2025InsiderDirector sold ~$607K of JAZZ shares in the open market
  3. Nov 26, 2025Insider · 1 personInsiders: 4 sales (~$13.8M)
  4. Dec 5, 2025Insider · 1 personInsiders: 2 sales (~$798K)
  5. Dec 9, 2025InsiderOfficer sold ~$379K of JAZZ shares in the open market
  6. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results
  7. Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
  8. Feb 26, 2026Insider · 3 peopleInsiders: 13 sales (~$11.9M)
  9. Feb 27, 2026Insider · 2 peopleInsiders: 2 sales (~$869K)
  10. Mar 3, 2026Insider · 1 personInsiders: 3 sales (~$1.1M)
  11. Mar 9, 2026InsiderOfficer sold ~$235K of JAZZ shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Jazz Pharmaceuticals

For Jazz Pharmaceuticals, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 10 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.

Other recent filings by Patricia Carr, SVP, Chief Accounting Officer

The full history of Patricia Carr, SVP, Chief Accounting Officer is on the profile page.

How this filing works

Other disclosures at Jazz Pharmaceuticals

Everything OQRO holds on this company is on its JAZZ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data